{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:19:19Z","timestamp":1790626759055,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,4,21]],"date-time":"2014-04-21T00:00:00Z","timestamp":1398038400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s13277-014-1836-x","type":"journal-article","created":{"date-parts":[[2014,4,20]],"date-time":"2014-04-20T04:47:21Z","timestamp":1397969241000},"page":"7009-7015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?"],"prefix":"10.1007","volume":"35","author":[{"given":"Roberto","family":"Angioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Capriglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Aloisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Guzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Luvero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Montera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Terranova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Plotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,21]]},"reference":[{"issue":"Suppl 2","key":"1836_CR1","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/S0020-7292(12)60025-3","volume":"119","author":"JS Berek","year":"2012","unstructured":"Berek JS, Crum C. Friedlander M Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2012;119 Suppl 2:S118\u201329.","journal-title":"Int J Gynaecol Obstet"},{"key":"1836_CR2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0889-8588(03)00058-3","volume":"17","author":"M Markman","year":"2003","unstructured":"Markman M. Optimizing primary chemotherapy in ovarian cancer. Hematol Oncol Clin North Am. 2003;17:957\u201368.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1836_CR3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2006.02.024","volume":"103","author":"M Markman","year":"2006","unstructured":"Markman M, Federico M, Liu PY, et al. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol. 2006;103:195\u20138.","journal-title":"Gynecol Oncol"},{"key":"1836_CR4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0305-7372(95)90002-0","volume":"21","author":"MK Tuxen","year":"1995","unstructured":"Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995;21:215\u201345.","journal-title":"Cancer Treat Rev"},{"key":"1836_CR5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0029-7844(02)02057-4","volume":"100","author":"BC Cooper","year":"2002","unstructured":"Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, et al. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol. 2002;100:59\u201364.","journal-title":"Obstet Gynecol"},{"key":"1836_CR6","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.1989.7.11.1667","volume":"7","author":"GJS Rustin","year":"1989","unstructured":"Rustin GJS, Gennings JN, Nelstrop AE, Covarrubias H, Lambert HE, Bagshawe KD. Use of CA-125 to predict survival of patients with ovarian carcinoma. J Clin Oncol. 1989;7:1667\u201371.","journal-title":"J Clin Oncol"},{"key":"1836_CR7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1525-1438.1997.00433.x","volume":"7","author":"NP Koper","year":"1997","unstructured":"Koper NP, Massuger LFAG, Thomas CMG, Kiemeney LALM, Schijf CPT, Beex LVAM, et al. Prognostic value of serial CA 125 measurements during chemotherapy for patients with advanced ovarian cancer. Int J Gynecol Cancer. 1997;7:127\u201333.","journal-title":"Int J Gynecol Cancer"},{"key":"1836_CR8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(92)90043-I","volume":"44","author":"O Mogensen","year":"1992","unstructured":"Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol. 1992;44:207\u201312.","journal-title":"Gynecol Oncol"},{"key":"1836_CR9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1046\/j.1525-1438.1996.06050380.x","volume":"6","author":"JA Latimer","year":"1996","unstructured":"Latimer JA, Beng CG, Davy MLJ. For stage III epithelial ovarian cancer the initial level of expression of CA 125 does not correlate with survival in women who respond to treatment. Int J Gynecol Cancer. 1996;6:380\u20134.","journal-title":"Int J Gynecol Cancer"},{"key":"1836_CR10","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/sj.bjc.6690744","volume":"81","author":"C Peters-Engl","year":"1999","unstructured":"Peters-Engl C, Obermair A, Heinzl H, Buxbaum P, Sevelda P, Medl M. CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer. Br J Cancer. 1999;81:662\u20136.","journal-title":"Br J Cancer"},{"key":"1836_CR11","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/(SICI)1097-0142(19960315)77:6<1122::AID-CNCR18>3.0.CO;2-3","volume":"77","author":"G Frasci","year":"1996","unstructured":"Frasci G, Conforti S, Zullo F, Mastrantonio P, Comella G, Comella P, et al. A risk model for ovarian carcinoma patients using CA 125. Cancer. 1996;77:1122\u201330.","journal-title":"Cancer"},{"key":"1836_CR12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ygyno.2009.04.019","volume":"114","author":"RP Rocconi","year":"2009","unstructured":"Rocconi RP, Matthews KS, Kemper MK, et al. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer. Gynecol Oncol. 2009;114:242\u20135.","journal-title":"Gynecol Oncol"},{"key":"1836_CR13","first-page":"16","volume-title":"WHO handbook for reporting results of cancer treatment (offset publication no. 48)","author":"World Health Organization","year":"1979","unstructured":"World Health Organization. WHO handbook for reporting results of cancer treatment (offset publication no. 48). Geneva: World Health Organization; 1979. p. 16\u201321."},{"key":"1836_CR14","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1006\/gyno.2000.5982","volume":"79","author":"A Dalen van","year":"2000","unstructured":"van Dalen A, Favier J, Burges A, Hasholzner U, de Bruijn HWA, Dobler-Girdziunaiti D, et al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol. 2000;79:444\u201350.","journal-title":"Gynecol Oncol"},{"key":"1836_CR15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","volume":"108","author":"RG Moore","year":"2008","unstructured":"Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402\u20138.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"1836_CR16","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s13277-012-0471-7","volume":"33","author":"F Plotti","year":"2012","unstructured":"Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiani P, et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol. 2012;33(6):2117\u201323.","journal-title":"Tumour Biol"},{"issue":"2","key":"1836_CR17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"key":"1836_CR18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205\u201316.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"1836_CR19","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1097\/IGC.0b013e3182225509","volume":"21","author":"J Hynninen","year":"2011","unstructured":"Hynninen J, Auranen A, Dean K, Lavonius M, Carpen O, Perheentupa A, et al. Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21(9):1573\u20138.","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"1836_CR20","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/IGC.0b013e31821e052e","volume":"21","author":"KD Steffensen","year":"2011","unstructured":"Steffensen KD, Waldstr\u00f8m M, Brandslund I, Jakobsen A. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients. Int J Gynecol Cancer. 2011;21(6):1040\u20137.","journal-title":"Int J Gynecol Cancer"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-014-1836-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-014-1836-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-014-1836-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T18:24:39Z","timestamp":1565375079000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-014-1836-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,21]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["1836"],"URL":"https:\/\/doi.org\/10.1007\/s13277-014-1836-x","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,21]]}}}